Background
==========

Bladder cancer is one of the most malignant tumors with high incidence and mortality during the past decades \[[@b1-medscimonit-25-3041]\]. In 2018, the incidence of bladder cancer was estimated to be approximately 81 000 new cases and the mortality to be 17 000 deaths in the United States (ranks sixth and eighth, respectively) \[[@b2-medscimonit-25-3041]\]. Histologically, approximately 95% of bladder cancer occurs in the urothelial cells, and around three-quarters of bladder cancer patients are non-muscle invasive bladder cancer while the rest are muscle invasive bladder cancer \[[@b3-medscimonit-25-3041]--[@b5-medscimonit-25-3041]\]. The grading of bladder cancer is crucial, and the World Health Organization (WHO) 2004/2016 grading system is preferred by most pathologists. Based on the cytologic and architectural abnormalities, atypia, low-grade, and high-grade determine the degree of malignancy and prognosis of bladder cancer \[[@b6-medscimonit-25-3041],[@b7-medscimonit-25-3041]\]. Although new strategies for cancer diagnosis, detection, and neo-treatments have been developed for patients with bladder cancer in the past 30 years, the 5-year relative survival rate is still unsatisfactory \[[@b8-medscimonit-25-3041]\]. Further research is thus essential to better understand the underlying pathogenetic mechanisms to improve the outcome of bladder cancer.

Recently, genetic characteristics and acquired genetic alterations have been found to play an important role in the bladder cancer. And these distinct mechanisms have been found to construct a multifocal network. For example, inactivating mutations in the tumor suppressor *TP53* and activating mutations in *FGFR3* are found in both papillary and non-papillary bladder cancer \[[@b9-medscimonit-25-3041],[@b10-medscimonit-25-3041]\]. Moreover, mutations in genes encoding transcription factors and chromatin-modifying enzymes and mutations in *TERT* promoter are also strongly implicated in some cases \[[@b11-medscimonit-25-3041]--[@b13-medscimonit-25-3041]\].

With the development of high-throughput sequencing methods, thousands of pseudogenes have been characterized \[[@b14-medscimonit-25-3041]\]. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been revealed to play a critical role in different kinds of cancer including bladder cancer, by modulating and modifying their ancestral gene. Our research group previously reported that lncRNA *ROR* was significantly increased in bladder cancer and positively associated with its potential targeting gene *ZBE1*, thereby contributing to the progression of bladder cancer as well as promoting epithelial-to-mesenchymal transition (EMT) \[[@b15-medscimonit-25-3041]\]. Liu et al. demonstrated that lncRNA *SRY4-IT1* sponges mir-101-3p and upregulates *EZH2* leading to aggressive phenotypes in bladder cancer \[[@b16-medscimonit-25-3041]\]. Therefore, characterization of an integrated whole differential gene expressions network with related endogenous RNA profiles is important, as it might play a key role in the pathogenesis of bladder cancer.

In this study, we identified the differentially expressed mRNA, lncRNA, and miRNA expression profiles in bladder cancer from the TCGA database. In addition, we performed functional analyses of the differentially expressed RNAs and investigated their clinical significance in relation to prognosis in bladder cancer.

Material and Methods
====================

Patients and pathological data
------------------------------

Transcriptome profiling data of 414 bladder cancer tissues and 19 normal bladder tissues were acquired from The Cancer Genome Atlas (TCGA) in October 2018. The RNA-seq data were generated from the Illumina HiSeqRNASeq and Illumina HiSeqmiRNASeq platforms. Using the GDC Data Transfer Tool (*<https://gdc.cancer.gov/access-data/gdc-data-transfer-tool>*), all the gene expression profiles and clinical data of bladder cancer were downloaded. Ethical consent was not required as all the data in this study were obtained from TCGA database.

Identification of differentially expressed RNA
----------------------------------------------

The "DESeq" package in R software \[[@b17-medscimonit-25-3041]\] was utilized to identify the differentially expressed RNAs in bladder cancer when compared to normal bladder tissues. The significance level of the adjusted *P*-value was set at *P*\<0.01 and the thresholds was set as \|log2FoldChange\| \>2. Moreover, the differentially expressed mRNAs, lncRNAs and miRNAs were annotated using ENSEMBL (*htps://[www.ensembl.org/](www.ensembl.org/)*).

CeRNA network construction
--------------------------

According to the ceRNA theory, lncRNAs can act as endogenous RNA and thereby regulating target gene transcripts by competing with shared miRNAs\[[@b18-medscimonit-25-3041]\]. Based on the differentially expressed mRNAs, lncRNAs and miRNAs in bladder cancer, the target mRNAs of the miRNAs were predicted by Targetscan (*<http://www.targetscan.org/>*), miRDB (*<http://www.mirdb.org/>*) and miRTarBase (*<http://mirtarbase.mbc.nctu.edu.tw/>*) \[[@b19-medscimonit-25-3041]\]. The miRanda database (*<http://www.microrna.org/>*) was used for the lncRNAs and miRNAs target predictions \[[@b20-medscimonit-25-3041]\]. In addition, by combining the discriminatory expression profiles data, the interaction between lncRNAs and mRNAs was identified. The ceRNA network of mRNA-lncRNA-miRNA was visualized with Cytoscape v3.6.2.

Functional enrichment analysis
------------------------------

Gene Ontology (GO) enrichment analysis was performed by (DAVID 6.8) database (*<http://david.abcc.ncifcrf.gov/>*) to group the differentially expressed RNAs into 3 categories including molecular function, biological process, and cellular component. The setting in the GO analysis was a false discovery rate (FDR) \<0.01. The "ClusterProfiler" package in R software was utilized to analyze the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. The barplots for GO and KEGG were generated by the "Goplot" package.

Prognosis risk scoring in differentially expressed RNAs
-------------------------------------------------------

Univariate Cox regression analysis was conducted where *P*\<0.0005 was considered statistically significant. The significant mRNAs in univariate Cox regression were subsequently analyzed in a multivariate Cox regression proportional hazards model. Furthermore, based on the median risk score, bladder cancer patients were divided into "high-risk" and "low-risk" groups. The risk scoring system was constructed by the formula as follows for predicting overall survival (OS): risk score=βg 1×exprg 1+βg 2×exprg 2+::: +βg n×exprg n \[[@b21-medscimonit-25-3041]\].

Kaplan-Meier survival analysis and receiver operating characteristic (ROC) analysis were then performed to assess the risk scoring system with high and low scores. The survival and ROC analyses were accomplished by using the R package "survival" and "survivalROC".

Protein--protein interaction (PPI) and correlation network construction
-----------------------------------------------------------------------

The differentially expressed mRNAs in the ceRNA network were analyzed through the protein--protein interaction (PPI) network. The PPI network was constructed with the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING). The minimum interaction value was set at low confidence (0.150). Based on the top 10 combined prediction score, we selected these gene expression profiles to perform correlation analyses for further validation.

Genes associated with grading and staging in ceRNA network and survival analysis
--------------------------------------------------------------------------------

Differentially expressed mRNA, lncRNA, and miRNA in the ceRNA network were analyzed in relation to low-grade and high-grade bladder cancer. These aberrantly expressed RNAs were also evaluated in relation to tumor stage. The significance level of adjusted *P*-value was \<0.01 and the thresholds was set as \|log2FoldChange\| \>2. Kaplan-Meier plots and log-rank test was performed to evaluate the genes in relation to overall survival, where *P*\<0.05 was considered as statistically significant.

Results
=======

Characteristics of clinical features in TCGA database
-----------------------------------------------------

Clinical information of bladder cancer patients from the TCGA database was available in 412 of 433 cases., The clinical characteristics including age, gender, tumor grade, tumor stage, and lymph node metastasis of the bladder cancer patients are presented in [Table 1](#t1-medscimonit-25-3041){ref-type="table"}. Interestingly, except for gender, all other clinical features were significantly associated with survival. Patients with high-grade bladder cancer were associated with worse outcomes compared to patients with low-grade bladder cancer. The median age of the cohort was 69 years (range: 34--90 years).

Differentially expressed RNAs and ceRNA network in bladder cancer
-----------------------------------------------------------------

A total of 1819 mRNAs, 659 lncRNAs, and 160 miRNAs were found to be differentially expressed in bladder cancer, of which 1030 mRNAs (56.7%), 415 lncRNAs (63.0%) and 139 miRNAs (86.9%) were upregulated while others were downregulated. The differentially expressed RNAs are visualized in the volcano plot ([Figure 1](#f1-medscimonit-25-3041){ref-type="fig"}). We further validated the relationships and functions of these differentially expressed RNAs according to the ceRNA hypothesis. The miRNA-mRNA and lncRNA-miRNA interactions were first predicted to find 52 mRNAs targeted by 17 key miRNAs involved in ceRNAs network ([Table 2](#t2-medscimonit-25-3041){ref-type="table"}) and 58 lncRNAs were predicted to be interacted with 22 miRNAs ([Table 3](#t3-medscimonit-25-3041){ref-type="table"}). As a result, 52 mRNAs, 58 lncRNAs, and 22 miRNAs of the differentially expressed RNAs were incorporated in the established ceRNA network ([Tables 4](#t4-medscimonit-25-3041){ref-type="table"}[](#t5-medscimonit-25-3041){ref-type="table"}--[6](#t6-medscimonit-25-3041){ref-type="table"}). In this ceRNA network, 16 mRNAs, 35 lncRNAs, and 17 miRNAs were downregulated; while 36 mRNAs, 23 lncRNAs, and 5 miRNAs were found to be upregulated ([Figure 2](#f2-medscimonit-25-3041){ref-type="fig"}).

GO and KEGG functional analysis
-------------------------------

To further elucidate the functions and biological processes of the differentially expressed mRNAs, we conducted the GO and KEGG enrichment analysis. The barplot of the GO analysis showed significant enrichment in 26 molecular functions, biological processes, and cellular components (*P*-value \<0.001) ([Figure 3A](#f3-medscimonit-25-3041){ref-type="fig"}). The results revealed that 313 genes were aggregated in extracellular region with the lowest *P*-value at 1.15E-36. KEGG pathway analysis showed that 20 pathways were associated with tumorigenesis of bladder cancer. As shown in [Figure 3B](#f3-medscimonit-25-3041){ref-type="fig"}, the neuroactive ligand-receptor interaction reflects the most significant cancer associated pathway which contained 61 genes, followed by alcoholism with 59 genes enriched.

Prognostic risk score based on differentially expressed mRNAs
-------------------------------------------------------------

Of the 1820 differentially expressed mRNAs, we found 36 mRNAs to be significantly associated with survival using univariate Cox regression ([Table 7](#t7-medscimonit-25-3041){ref-type="table"}). Subsequently, multivariate Cox regression was applied, and 12 mRNA expression profiles were identified as coupled to overall survival and included in the overall survival prediction model ([Figure 4A, 4B](#f4-medscimonit-25-3041){ref-type="fig"}). On the basis of the overall survival prediction model, a prognostic risk model was constructed where the high-risk group was significantly associated with lower overall survival (*P*\<0.05) ([Figure 4B](#f4-medscimonit-25-3041){ref-type="fig"}). The discriminative evaluation of the risk scoring system was performed with ROC-curve analysis where we found an AUC=0.735 ([Figure 4C](#f4-medscimonit-25-3041){ref-type="fig"}).

PPI network
-----------

In order to identify the gene interactions of the differentially expressed mRNAs in the ceRNA network, a PPI network was constructed with these 52 aberrantly expressed genes. In total, 44 nodes and 144 edges were constituted in the single PPI network by STRING ([Figure 5A](#f5-medscimonit-25-3041){ref-type="fig"}). *JUN* was identified to have the largest number of edges interacting with 28 other genes. Nodes which connect with more than 4 genes are listed in the barplot ([Figure 5B](#f5-medscimonit-25-3041){ref-type="fig"}). Based on the predicted combined score for each pair of nodes from STRING, the top 10 correlating mRNAs are presented in [Table 8](#t8-medscimonit-25-3041){ref-type="table"}. We then proceeded by validating the 10 correlations with Pearson's correlation and as shown in [Figure 6](#f6-medscimonit-25-3041){ref-type="fig"}, we found a strong correlation between CFL2 and TPM2 (r=0.911) and between CCNE2 and E2F7 (r=0.734), respectively ([Figure 6](#f6-medscimonit-25-3041){ref-type="fig"}). The results indicated that there was an interaction between CFL2 and TPM2 and between CCNE2 and E2F7 respectively, in bladder cancer.

Clinicopathological features related gene expression in ceRNA network
---------------------------------------------------------------------

We further analyzed the relationship between the differentially expressed RNAs in the ceRNA network in relation to clinicopathological features. As a result, we found 5 mRNAs, 21 lnRNAs, and 6 miRNAs to be differentially expressed among high-grade and low-grade bladder cancer ([Figure 7](#f7-medscimonit-25-3041){ref-type="fig"}, [Table 9](#t9-medscimonit-25-3041){ref-type="table"}). In addition, of these RNAs, 2 out of 5 mRNAs (*HOXB5*,*MKX*) and 10 out of 21 lncRNAs (*AC112721.1*, *ADAMTS9-AS1*, *AP004609.1*, *LINC00460*, *AC110491.1*, *C20orf166-AS1*, *LINC00163*, *ARAP1-AS1*, *HCG22*, *LINC00473*) were found to be significantly differentially expressed across stage I, stage II, stage III, and stage IV ([Figure 8](#f8-medscimonit-25-3041){ref-type="fig"}). The rest of the RNAs were not associated with tumor stage in bladder cancer (*P*\>0.05) ([Supplementary Figure 1](#s1-medscimonit-25-3041){ref-type="supplementary-material"}). In relation to prognosis, 1 mRNA (*HOXB5*) and 6 lncRNAs (*ADAMTS9-AS1*, *AC112721.1*, *LINC00460*, *AC110491.1*,*LINC00163*, *HCG22*) were observed to be associated with overall survival ([Figure 9](#f9-medscimonit-25-3041){ref-type="fig"}).

Discussion
==========

Molecular and genetic alterations in bladder cancer have been extensively studied in the past decades. Clinicopathological features, including tumor grade and stage have been shown to be linked to biological and genetic mechanisms \[[@b22-medscimonit-25-3041]--[@b24-medscimonit-25-3041]\]. However, clinical challenges still exist for bladder cancer making it crucial to focus on new prediction methods based on the molecular targets.

In this study, we have conducted an integrated characterization of RNA expression profiles and performed ceRNA network analysis in bladder cancer based on data from the TCGA database. As a result, 1819 mRNAs, 659 lncRNAs, and 160 miRNAs were found to be differentially expressed in bladder cancer, of which 52 mRNAs, 58 lncRNAs, and 22 miRNAs were predicted to be involved in the ceRNA network. Furthermore, high-grade bladder cancer related RNA profiles were identified consisting of 5 mRNAs, 21 lnRNAs, and 6 mRNAs, of which 2 mRNAs and 10 lncRNAs were found to be associated with stage as well.

Based on the current findings of 1819 differentially expressed RNAs, our functional enrichment analysis indicated that that these genes were mainly enriched in "extracellular region". Similarly, GO analysis of prostate cancer conducted by Jiang et al. showed that most of the differentially expressed mRNAs in the urinary system were aggregated in the extracellular region \[[@b25-medscimonit-25-3041]\]. In addition, we predicted that 61 genes were enriched in the neuroactive ligand-receptor interaction, including *PDGFR-*α. Activation of *PDGFR-*α have previously been implicated in bladder tumor progression by a ras- and Src-independent activation of MEK/ERK pathway \[[@b26-medscimonit-25-3041]\]. Interestingly, systematic lupus erythematosus and alcoholism were identified as important components in the occurrence and development of bladder cancer as previous reported \[[@b27-medscimonit-25-3041],[@b28-medscimonit-25-3041]\].

Based on the results from the Cox regression, we successfully established an overall survival prediction model based on 12 mRNA expression profiles. The discriminative value of these genes combined was an AUC at 0.735. Of these 12 genes, the tumor necrosis factor-α induced protein 8 *TNFAIP8*, has been shown to be strongly associated to cancer progression \[[@b29-medscimonit-25-3041]\]. However, except for *TNFAIP8* in the prediction model, the other 11 genes have not yet been elucidated in bladder cancer. Hence, the prognostic value of the prediction model should be further demonstrated in future studies.

Through our analysis of the PPI network, we identified that *JUN*, known as c-Jun, plays a vital role in the differentially expressed mRNAs in our ceRNA network. In the analysis, we found that *JUN* has the most edges and interacts with 28 other genes.*JUN* is an AP-1 transcription factor subunit, which exhibits proto-oncogenic functions, and several studies have previously validated that the tumorigenesis of bladder cancer has frequently occurred through c-jun relevant signaling pathways \[[@b30-medscimonit-25-3041]--[@b34-medscimonit-25-3041]\]. Moreover, Chen et al. reported that *TMP2* expression was significantly decreased in bladder cancer \[[@b35-medscimonit-25-3041]\], which was in accordance with our findings that demonstrated the strong positive correlation between *TPM2* and *CFL2* expressions, where *CFL2* was also found to be downregulated in bladder cancer with the lowest FDR. *CFL2* has also been reported to act as a tumor suppressor gene in nasopharyngeal carcinoma, pancreas cancer, and gastric cancer \[[@b36-medscimonit-25-3041]--[@b38-medscimonit-25-3041]\]. Although the functions of *CFL2* in bladder cancer has not yet been studied comprehensively, our results indicated that it is a promising novel and potentially meaningful biomarker for exploring new mechanisms in bladder cancer.

As we know, clinicopathological features such as grading and staging are systematic and important prognostic factors in bladder cancer, but their relationship to gene expression profiles remains unclear. In our study, we constructed a bladder cancer specific ceRNA network and analyzed the differentially expressed mRNAs and endogenous RNAs in relation to tumor grades and stages. As a result, we identified that 2 mRNAs and 10 lncRNAs were significantly associated to high-grade tumors and different stages. However, in survival analyses, only *HOXB5* and 6 lncRNAs (*ADAMTS9-AS1*, *AC112721.1*, *LINC00460*, *AC110491.1*, *LINC00163*, *HCG22*) were related to overall survival. Although *HOXB5* is upregulated in bladder cancer correlating with high-grade and high-stage tumors and has a miRNA-7-binding site of HOXB5 3′-UTR SNP \[[@b39-medscimonit-25-3041]\], the mechanisms of *HOXB5* in bladder cancer remains to be further explored in future studies. Of the survival related lncRNAs in our study, Ye et al. previously demonstrated that *LINC00460* could facilitate tumor progression by acting as a sponge to *miR-302c-5p* and thereby regulating FOXA1 signaling pathway in human lung adenocarcinoma; *LINC00460* has also been implicated in promoting malignant biological behaviors in gastric cancer by regulating *KDM2A* expression through the targeting of *miR-342-3p* \[[@b40-medscimonit-25-3041],[@b41-medscimonit-25-3041]\]. However, none of the 6 survival-related lncRNAs have been reported in bladder cancer. In summary, we identified that *HOXB5*, *ADAMTS9-AS1*, *AC112721.1*, *LINC00460*, *AC110491.1*, *LINC00163*, and *HCG22* were related to overall survival in bladder cancer. These genes could be promising future biomarkers for diagnosis, prognostication, and also neo-therapeutic targets in bladder cancer.

Conclusions
===========

We have identified a large number of differentially expressed mRNAs, lncRNAs, and miRNAs in bladder cancer which were strongly associated with oncogenesis and prognosis. Many of these RNAs have not been reported in the current literature as related to bladder cancer and represent novel and promising future targets. However, larger cohorts of patients and future mechanistic studies are necessary to validate our results, and investigate their functional roles in bladder cancer.

Supplementary Figure
====================

###### 

Histograms of differentially expressed genes in the ceRNA network unrelated to high-grade and stages. (**A**) Three mRNAs expressions were unrelated to tumor stages. (**B**) Eleven lncRNAs expressions were unrelated to tumor stages. (**C**) Six mRNAs expressions were unrelated to tumor stages.
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![Differentially expressed RNAs in bladder cancer are visualized by volcano plots. The red dots show upregulated genes while the green dots show downregulated genes. (**A**) Differentially expressed mRNAs in bladder cancer. (**B**) Differentially expressed lncRNAs in bladder cancer. (**C**) Differentially expressed miRNAs in bladder cancer.](medscimonit-25-3041-g001){#f1-medscimonit-25-3041}

![The ceRNA network of differentially expressed RNA profiles in bladder cancer, the upregulated genes are presented using red color while downregulated genes are shown using green color. Circles represent mRNAs, quadrangles represent lncRNAs and rhombus represent miRNAs.](medscimonit-25-3041-g002){#f2-medscimonit-25-3041}

![GO and KEGG analysis of differentially expressed mRNAs in bladder cancer. (**A**) Twenty-six significant molecular functions, biological processes, and cellular components of differentially expressed mRNAs. (**B**) Twenty enrichment of KEGG pathways for differentially expressed mRNAs. GO -- Gene Ontology; KEGG -- Kyoto Encyclopedia of Genes and Genomes.](medscimonit-25-3041-g003){#f3-medscimonit-25-3041}

![Survival analysis and Cox regression. (**A**) A heatmap of 12 significant mRNA expression profile for prediction of overall survival by multivariate cox regression. (**B**) Twelve mRNA expression profiles for prediction of overall survival in bladder cancer by multivariate Cox regression (**C**) Kaplan-Meier plot shows statistical significance between high-risk and low-risk groups by risk scoring model (*P*\<0.05). (**D**) The ROC curve for the risk scoring model (AUC=0.735). ROC -- receiver operating characteristic; AUC -- area under the curve.](medscimonit-25-3041-g004){#f4-medscimonit-25-3041}

![The protein--protein interaction (PPI) network. (**A**) A PPI network of differentially expressed genes in the ceRNA network. (**B**) The order of different edges of each gene in the PPI network.](medscimonit-25-3041-g005){#f5-medscimonit-25-3041}

![The correlation plots of the top 10 predicted combined model.](medscimonit-25-3041-g006){#f6-medscimonit-25-3041}

![A heatmap of differentially expressed genes in the ceRNA network associated with high-grade bladder cancer. (**A**) Differentially expressed mRNAs in ceRNA network associated with high-grade bladder cancer. (**B**) Differentially expressed lncRNAs in ceRNA network associated with high-grade bladder cancer. (**C**) Differentially expressed miRNAs in ceRNA network associated with high-grade bladder cancer.](medscimonit-25-3041-g007){#f7-medscimonit-25-3041}

![Histograms of differentially expressed genes in the ceRNA network related to high-grade bladder cancer and disease stages. (**A**) Two significant mRNA expressions across different tumor stages. (**B**) Ten significant lncRNAs expressions across different tumor stages.](medscimonit-25-3041-g008){#f8-medscimonit-25-3041}

![The Kaplan-Meier plots of differentially expressed RNAs in the ceRNA network which are also related to high-grade, stages, and overall survival.](medscimonit-25-3041-g009){#f9-medscimonit-25-3041}

###### 

The clinicopathological characteristics of bladder cancer patients.

  Characteristics    Subtype          Patinets n (%)   Dead   χ^2^     P-value
  ------------------ ---------------- ---------------- ------ -------- ---------
  Age                \>65             250 (60.7)       115    14.722   \<0.01
  ≤65                162 (39.3)       44                               
  Gender             Male             304 (73.8%)      115    0.285    0.593
  Female             108 (26.2%)      44                               
  Tumor grade        High grade       388 (94.2%)      159    16.016   \<0.01
  Low grade          24 (5.8%)        0                                
  Tumor Stage        Stage I and II   133 (32.3%)      27     27.728   \<0.01
  Stage III and IV   279 (67.7%)      132                              
  Lymph node         Negative         239 (58.0%)      63     37.810   \<0.01
  Positive           131 (31.8%)      77                               
  Unknow             42 (10.2%)       19                               

N=412.

###### 

Differentially expressed miRNAs targeting mRNAs in the ceRNA network.

  miRNA      mRNA
  ---------- ----------------------------------------------------------------------------------------------------------------
  miR-141    EPHA7; ZEB1; ELAVL2; HOXB5
  miR-145    MEST
  miR-182    FGF9; THBS1; TCEAL7; ULBP2; PRKAA2
  miR-183    AKAP12; ZEB1; CCNB1
  miR-195    BTG2; TPM2; RUNX1T1; FGF2; TGFBR3; CBX2; PRICKLE2; MYB; WNT7A; MKX; ALOX12; ITPR1; CCNE1; RAB23; TMEM100; E2F7
  miR-200a   HOXB5; EPHA7; ZEB1; ELAVL2; CCNE2
  miR-205    ZEB1; SHISA6; LRRK2
  miR-210    SERTM1; AIFM3; NR4A2
  miR-217    NR4A2; MAP1B
  miR-31     SELE; HOXC13
  miR-372    DUSP2; CADM2; TMEM100; FBXL7; ELAVL2
  miR-373    CADM2; TMEM100; FBXL7; ELAVL2; CFL2; DUSP2
  miR-383    DIO1
  miR-429    JUN; ZEB1; ZFPM2
  miR-503    GREM2
  miR-519d   NACC2; HMGB3; CYBRD1; SALL3; CFL2; FAM129A; DUSP2; POLQ; ELAVL2
  miR-96     SLC25A25; ZEB1

###### 

Differentially expressed miRNAs targeting lncRNAs in ceRNA network.

  LncRNA            miRNA
  ----------------- ---------------------------------------------------------------------------------------------------------------------
  IGF2-AS           miR-519d; miR-503
  LINC00525         miR-301b; miR-96; miR-141; miR-200a; miR-182; miR-31; miR-383
  PART1             miR-301b; miR-141; miR-200a; miR-143; miR-145; miR-195; miR-429; miR-205; miR-31
  AC009065.1        miR-372; miR-373
  C20orf166-AS1     miR-301b; miR-372; miR-373; miR-519d; miR-183; miR-429; miR-205; miR-489
  GRIK1-AS1         miR-145; miR-205; miR-383
  C20orf197         miR-372; miR-373; miR-143; miR-519d; miR-383
  AP002478.1        miR-503; miR-372; miR-373; miR-195; miR-519d; miR-182; miR-192; miR-215; miR-205; miR-489
  LINC00518         miR-141; miR-200a; miR-143; miR-145
  LINC00482         miR-143
  MIR22HG           miR-383; miR-489
  C9orf163          miR-143; miR-195; miR-205; miR-489
  LINC00336         miR-96; miR-143; miR-145; miR-217
  AC008676.1        miR-301b; miR-372; miR-373; miR-141; miR-200a; miR-143; miR-519d; miR-31
  LINC00487         miR-372; miR-373; miR-143; miR-183; miR-205; miR-31
  AP000525.1        miR-503; miR-31
  AC104472.1        miR-143; miR-183; miR-429; miR-31; miR-489
  AL513123.1        miR-141; miR-200a; miR-183
  LINC00473         miR-145; miR-195; miR-210
  LINC00337         miR-372; miR-373; miR-145; miR-519d; miR-182; miR-217; miR-383
  AC127496.3        miR-301b; miR-372; miR-373; miR-145; miR-183; miR-192; miR-215; miR-429
  LINC00161         miR-145; miR-205
  HCG22             miR-96; miR-145; miR-195; miR-182; miR-31; miR-383; miR-489
  **SACS-AS1**      miR-503; miR-372; miR-143; miR-205
  **MIR137HG**      miR-182; miR-192; miR-215;
  **RASA3-IT1**     miR-205; miR-383
  **NALCN-AS1**     miR-372; miR-373; miR-195; miR-182; miR-205; miR-31; miR-383
  **ERVH48-1**      miR-301b; miR-96; miR-141; miR-200a; miR-145; miR-182
  **LINC00472**     miR-503; miR-372; miR-373; miR-141; miR-200a; miR-143; miR-145; miR-195; miR-383; miR-489
  **AC110491.1**    miR-141; miR-200a; miR-143; miR-182; miR-192; miR-215; miR-429; miR-205; miR-489
  **TLR8-AS1**      miR-182; miR-31
  **LINC00460**     miR-503; miR-143; miR-429; miR-489
  **JAZF1-AS1**     miR-372; miR-373; miR-143; miR-519d; miR-205
  **MAGI2-AS3**     miR-503; miR-372; miR-373; miR-141; miR-200a; miR-143; miR-145; miR-195; miR-429; miR-210; miR-217; miR-31; miR-489
  **LINC00163**     miR-143; miR-183; miR-210
  **LINC00330**     miR-503; miR-301b; miR-372; miR-373; miR-145; miR-195; miR-519d; miR-192; miR-215; miR-205; miR-383
  **LINC00402**     miR-141; miR-200a; miR-143; miR-519d; miR-182; miR-429; miR-217; miR-383
  **TM4SF19-AS1**   miR-141; miR-200a; miR-205
  **MYO16-AS1**     miR-489
  **DLEU7-AS1**     miR-96; miR-195; miR-182; miR-192; miR-215
  **AC009121.1**    miR-141; miR200a
  **AC112721.1**    miR-503; miR-195
  **AP004609.1**    miR-383
  **ADAMTS9-AS1**   miR-301b; miR-96; miR-145; miR-182; miR-31
  **HNF1A-AS1**     miR-372; miR-373; miR-141; miR-200a; miR-195; miR-519d; miR-183; miR-217
  **ADAMTS9-AS2**   miR-301b; miR-372; miR-373; miR-96; miR-141; miR-200a; miR-143; miR-145; miR-182; miR-183; miR-205; miR-31
  **AC078778.1**    miR-301b
  **AC012640.1**    miR-182; miR-205; miR-210; miR-383
  **AC073352.1**    miR-96; miR-182
  **AC011453.1**    miR-143; miR-205
  **AP000553.1**    miR-192; miR-215; miR-217
  **AC128709.1**    miR-503; miR-195; miR-183
  **LINC00534**     miR-372; miR-373; miR-96; miR-192; miR-215; miR-205; miR-217; miR-489
  **NAV2-AS2**      miR-96; miR-182; miR-31
  **ARAP1-AS1**     miR-145
  **FRMD6-AS2**     miR-143; miR-182
  **LINC00520**     miR-503; miR-372; miR-373; miR-145; miR-195; miR-519d; miR-205; miR-217; miR-31

###### 

Differentially expressed mRNAs in ceRNA network.

  DEmRNAs    Regulation        Log fold change   FDR
  ---------- ----------------- ----------------- ----------
  CFL2       Down-regulation   −3.18787341       6.81E-64
  SLC25A25   Down-regulation   −2.656571564      1.81E-63
  FAM129A    Down-regulation   −3.684416254      2.52E-60
  NACC2      Down-regulation   −2.417159742      5.74E-48
  RAB23      Down-regulation   −2.902696027      1.86E-43
  ITPR1      Down-regulation   −2.677318488      4.37E-38
  ZEB1       Down-regulation   −2.830314677      2.64E-37
  MAP1B      Down-regulation   −3.224125414      1.18E-34
  NR4A2      Down-regulation   −2.806554541      9.69E-33
  TPM2       Down-regulation   −3.056564907      1.34E-30
  FBXL7      Down-regulation   −2.52708691       5.43E-28
  THBS1      Down-regulation   −2.686696518      7.25E-25
  PRICKLE2   Down-regulation   −2.241943352      9.47E-25
  JUN        Down-regulation   −2.081270648      1.94E-23
  ZFPM2      Down-regulation   −2.664653755      3.11E-23
  AKAP12     Down-regulation   −2.592811618      8.39E-22
  TMEM100    Down-regulation   −3.095618096      4.25E-20
  TCEAL7     Down-regulation   −2.49946          5.49E-20
  EPHA7      Down-regulation   −3.166            9.53E-20
  FGF2       Down-regulation   −2.69593          9.99E-19
  RUNX1T1    Down-regulation   −2.57174          1.52E-18
  LRRK2      Down-regulation   −2.36765          2.55E-18
  BTG2       Down-regulation   −2.13366          6.79E-18
  CYBRD1     Down-regulation   −2.17256          8.81E-18
  MKX        Down-regulation   −3.12218          1.49E-17
  HMGB3      Up-regulation     2.057653          1.33E-16
  PRKAA2     Down-regulation   −2.63399          1.31E-15
  POLQ       Up-regulation     2.442571          1.38E-15
  TGFBR3     Down-regulation   −2.0693           2.90E-15
  DUSP2      Down-regulation   −2.49447          8.28E-15
  GREM2      Down-regulation   −3.03523          2.37E-14
  CCNB1      Up-regulation     2.066358          1.53E-12
  SERTM1     Down-regulation   −3.83855          2.49E-12
  SHISA6     Down-regulation   −2.77251          3.62E-11
  CCNE1      Up-regulation     2.305447          2.37E-10
  FGF9       Up-regulation     2.519249          2.45E-10
  SELE       Down-regulation   −2.78825          7.82E-10
  E2F7       Down-regulation   −2.47734          1.80E-09
  CCNE2      Up-regulation     2.254535          6.75E-09
  ALOX12     Up-regulation     2.116593          6.91E-09
  ULBP2      Down-regulation   −2.00117          1.01E-08
  MEST       Up-regulation     2.464683          7.47E-08
  CBX2       Up-regulation     2.595458          1.57E-06
  CADM2      Up-regulation     2.183717          3.23E-06
  HOXC13     Down-regulation   −2.25318          2.10E-05
  MYB        Up-regulation     2.796581          4.20E-05
  SALL3      Up-regulation     2.034968          4.76E-05
  AIFM3      Down-regulation   −2.55675          0.000173
  HOXB5      Up-regulation     2.147751          0.000211
  WNT7A      Up-regulation     2.024795          0.000334
  ELAVL2     Up-regulation     6.532413          0.000532
  DIO1       Up-regulation     3.143323          0.000581

###### 

Differentially expressed lncRNAs in ceRNA network.

  DELncRNAs       Regulation        Log fold change   FDR
  --------------- ----------------- ----------------- -------------
  HCG22           Down-regulation   −7.393236357      8.70E-86
  ADAMTS9-AS1     Down-regulation   −5.173460141      1.28E-59
  ADAMTS9-AS2     Down-regulation   −4.152710881      3.17E-50
  LINC00330       Down-regulation   −5.357713971      8.39E-35
  C20orf166-AS1   Down-regulation   −4.418702998      7.39E-34
  MIR22HG         Down-regulation   −2.186866609      2.83E-29
  JAZF1-AS1       Down-regulation   −3.248756128      2.20E-26
  AC008676.1      Down-regulation   −2.677691052      1.61E-22
  RASA3-IT1       Down-regulation   −4.319901412      8.29E-20
  MAGI2-AS3       Down-regulation   −2.271922028      1.15E-18
  FRMD6-AS2       Down-regulation   −3.536986684      6.70E-18
  PART1           Down-regulation   −2.883633316      5.25E-16
  AC110491.1      Down-regulation   −3.809886233      5.66E-16
  AC078778.1      Up-regulation     2.171874229       2.62E-14
  SACS-AS1        Down-regulation   −3.387765888      1.98E-13
  AP004609.1      Down-regulation   −2.579281355      2.67E-11
  C9orf163        Up-regulation     2.339600002       6.13E-11
  LINC00472       Down-regulation   −2.086567223      5.03E-10
  AC127496.3      Down-regulation   −2.916229805      7.40E-10
  GRIK1-AS1       Down-regulation   −2.185078089      8.15E-10
  AC073352.1      Up-regulation     2.540191221       4.51E-09
  NALCN-AS1       Down-regulation   −2.49519035       8.70E-09
  AP000553.1      Up-regulation     3.216908948       1.44E-08
  LINC00163       Down-regulation   −2.829231994      1.25E-07
  AC009121.1      Up-regulation     2.162583137       1.08E-06
  LINC00460       Up-regulation     7.163558998       1.22E-06
  DLEU7-AS1       Up-regulation     2.139118702       3.54E-06
  LINC00337       Up-regulation     2.018174432       4.36E-06
  AP000525.1      Up-regulation     2.750867634       1.26E-05
  AL513123.1      Up-regulation     3.339752428       1.64E-05
  LINC00161       Down-regulation   −2.004179345      2.13E-05
  LINC00402       Down-regulation   −2.228396776      2.28E-05
  C2orf48         Up-regulation     2.234385723       2.41E-05
  AC112721.1      Up-regulation     5.679017823       2.64E-05
  ERVH48-1        Up-regulation     6.171777638       3.07E-05
  TM4SF19-AS1     Up-regulation     2.241213677       5.71E-05
  LINC00525       Up-regulation     2.388170307       7.58E-05
  AP002478.1      Up-regulation     2.499724256       7.88E-05
  AC011453.1      Up-regulation     4.106228298       0.000145979
  C20orf197       Up-regulation     3.222909721       0.000173251
  LINC00487       Up-regulation     2.684913886       0.00019263
  AC012640.1      Up-regulation     3.267430057       0.000198949
  AC009065.1      Up-regulation     2.029597356       0.000245796
  LINC00518       Up-regulation     4.436236799       0.000596273
  AC104472.1      Up-regulation     2.743663788       0.001205612
  MYO16-AS1       Up-regulation     4.783639374       0.001480169
  HNF1A-AS1       Up-regulation     3.838602554       0.001551329
  LINC00534       Up-regulation     2.943676684       0.002062953
  LINC00520       Up-regulation     3.918845469       0.002229151
  LINC00482       Up-regulation     2.211556791       0.003470315
  LINC00473       Down-regulation   −2.010751587      0.003738568
  LINC00336       Up-regulation     2.001908125       0.003803458
  TLR8-AS1        Up-regulation     4.005367912       0.003995111
  MIR137HG        Up-regulation     5.171531584       0.004865838
  NAV2-AS2        Up-regulation     3.18541719        0.006297113
  ARAP1-AS1       Up-regulation     3.214443621       0.007268128
  AC128709.1      Up-regulation     2.114272765       0.008604833
  IGF2-AS         Up-regulation     2.399553974       0.008980377

###### 

Differentially expressed lncRNAs in ceRNA network.

  DEmiRNAs         Regulation        Log fold change   FDR
  ---------------- ----------------- ----------------- -------------
  hsa-mir-143      Down-regulation   −3.525679542      1.28E-41
  hsa-mir-195      Down-regulation   −2.410426303      1.25E-32
  hsa-mir-96       Up-regulation     3.767149943       8.97E-18
  hsa-mir-210      Up-regulation     4.973834298       1.33E-17
  hsa-mir-3199-2   Down-regulation   −2.187131639      1.55E-15
  hsa-mir-145      Down-regulation   −2.133372137      3.72E-14
  hsa-mir-183      Up-regulation     3.03501324        8.81E-14
  hsa-mir-301b     Up-regulation     3.971849748       1.19E-12
  hsa-mir-141      Up-regulation     2.631026555       3.23E-11
  hsa-mir-503      Up-regulation     2.473934298       3.22E-10
  hsa-mir-182      Up-regulation     2.348870325       3.51E-10
  hsa-mir-429      Up-regulation     2.758180811       6.74E-09
  hsa-mir-383      Down-regulation   −2.801221137      3.16E-08
  hsa-mir-200a     Up-regulation     2.219506844       2.94E-07
  hsa-mir-192      Up-regulation     2.40248191        6.49E-07
  hsa-mir-205      Up-regulation     2.239011007       8.69E-06
  hsa-mir-215      Up-regulation     4.242318245       2.68E-05
  hsa-mir-31       Up-regulation     2.786222534       3.19E-05
  hsa-mir-3136     Up-regulation     2.306880974       4.63E-05
  hsa-mir-519d     Up-regulation     7.14700051        0.000164482
  hsa-mir-372      Up-regulation     5.986379084       0.000186072
  hsa-mir-489      Up-regulation     2.962732727       0.000303842

###### 

Significant genes demonstrated in univariate Cox regression model (P\<0.005).

  Gene        HR            z-score        P-value
  ----------- ------------- -------------- -------------
  EMP1        1.328762282   5.254914697    1.48E-07
  MXRA7       1.432626177   4.705964739    2.53E-06
  SERPINB12   1.162296991   4.580143916    4.65E-06
  MAP1B       1.229296929   4.37622915     1.21E-05
  LAMA2       1.267134732   4.327829003    1.51E-05
  MAP1A       1.233776119   4.250957967    2.13E-05
  KANK4       1.113571638   4.182201609    2.89E-05
  ABCC9       1.231009469   4.178191876    2.94E-05
  PEX5L       1.162984335   4.138450231    3.50E-05
  PTGER3      1.144526818   4.026382546    5.66E-05
  PTPRR       0.898457289   −3.961993355   7.43E-05
  POU5F1      0.857411853   −3.875204799   0.000106535
  PCSK9       1.102595243   3.853707011    0.000116343
  TCHH        1.135841746   3.841592708    0.000122239
  SAPCD1      0.791832106   −3.813548024   0.000136986
  GABRG1      1.312711858   3.80120357     0.000143995
  CNTN1       1.105824108   3.792658288    0.000149043
  ADCYAP1R1   1.159131884   3.76366481     0.000167441
  CCDC80      1.145437466   3.757189589    0.000171832
  DTNA        1.138932514   3.75592982     0.000172699
  PID1        1.179886946   3.740557523    0.000183613
  RBMS3       1.203510811   3.693371944    0.0002213
  XAGE2       1.105072802   3.689802104    0.000224429
  PLEKHG4B    1.096473367   3.681482901    0.000231881
  NTNG1       1.118858872   3.676085951    0.00023684
  FBN2        1.108316893   3.656143873    0.000256038
  FLNC        1.112773551   3.62254181     0.000291722
  GHR         1.161660284   3.622453812    0.000291822
  PRKG1       1.195566092   3.621918942    0.000292426
  TNFAIP8L3   1.171369232   3.611019416    0.000304996
  ADRA1D      1.17070966    3.553028545    0.000380823
  AIFM3       0.853346363   −3.547409751   0.000389039
  ABCA4       1.103837888   3.521258054    0.000429504
  SRPX        1.146802308   3.515246382    0.000439346
  CACNA2D1    1.156053229   3.499144698    0.000466753

###### 

Top 10 correlating mRNAs presented in the protein--protein interaction network.

  mRNA1   mRNA2   Combined score
  ------- ------- ----------------
  JUN     MYB     0.973
  MYB     CCNB1   0.964
  CCNE1   CCNB1   0.949
  JUN     SELE    0.949
  E2F7    CCNE2   0.925
  FGF9    FGF2    0.919
  CCNE2   CCNE1   0.91
  FGF2    THBS1   0.861
  JUN     FGF2    0.811
  TPM2    CFL2    0.793

###### 

Differentially expressed RNA profiles correlating to high-grade bladder cancer from the ceRNA network.

  RNAs                    Log fold change   FDR
  ----------------------- ----------------- -------------
  HOXB5(mRNA)             −2.944596082      2.39E-18
  MKX(mRNA)               3.512064708       3.98E-08
  SALL3(mRNA)             −3.009599773      6.86E-07
  ELAVL2(mRNA)            3.104383407       0.000197897
  SELE(mRNA)              2.275611899       0.000649315
  LINC00336(lncRNA)       −2.274109048      1.50E-09
  ARAP1-AS1(lncRNA)       −2.922663469      3.31E-09
  LINC00460(lncRNA)       6.246084381       1.13E-06
  AC112721.1(lncRNA)      6.126188656       1.90E-06
  ADAMTS9-AS1(lncRNA)     4.959254878       8.37E-06
  C2orf48(lncRNA)         2.14039587        2.37E-05
  MIR137HG(lncRNA)        6.327534674       5.76E-05
  LINC00473(lncRNA)       5.415263905       6.33E-05
  LINC00163(lncRNA)       4.423919282       6.33E-05
  AC110491.1(lncRNA)      4.746368747       0.000165643
  LINC00402(lncRNA)       3.533793424       0.000229383
  MYO16-AS1(lncRNA)       5.102890553       0.000231527
  LINC00520(lncRNA)       4.493602761       0.000289874
  HCG22(lncRNA)           6.362121452       0.000499845
  TLR8-AS1(lncRNA)        4.019357381       0.000964633
  C20orf166-AS1(lncRNA)   3.194349357       0.001177387
  LINC00518(lncRNA)       2.965146588       0.004120812
  AP004609.1(lncRNA)      2.067991973       0.004431844
  SACS-AS1(lncRNA)        2.266344736       0.026097183
  LINC00330(lncRNA)       3.348989332       0.026097183
  AC127496.3(lncRNA)      2.19115354        0.034777432
  hsa-mir-143(miRNA)      3.330527062       0.00099772
  hsa-mir-215(miRNA)      2.871943848       0.002121278
  hsa-mir-217(miRNA)      3.321184311       0.002354727
  hsa-mir-372(miRNA)      4.593394591       0.00371048
  hsa-mir-373(miRNA)      4.640595006       0.0118349
  hsa-mir-383(miRNA)      2.381514994       0.024564256
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